(Q37028215)

17 August 2017

1 reference

title

Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin (English)

1 reference

17 August 2017

1 reference

3

Edward K Geissler

1 reference

17 August 2017

Andreas Gaumann

1

1 reference

17 August 2017

Hans J Schlitt

series ordinal

2

1 reference

17 August 2017

language of work or name

1 reference

5 December 2007

1 reference

17 August 2017

published in

Transplant International

1 reference

17 August 2017

volume

21

1 reference

17 August 2017

issue

3

1 reference

17 August 2017

page(s)

207-217

1 reference

Cyclosporin a inhibits interleukin 2-dependent growth of alloactivated cloned human T-lymphocytes

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Immunosuppressive drugs and the risk of cancer after organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Malignancies in organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Non-melanoma skin cancer risk in the Queensland renal transplant population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Skin cancers after organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Sirolimus: its discovery, biological properties, and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Effects of cyclosporin A and a rapamycin derivative (SAR943) on chronic allergic inflammation in sensitized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Resistance to rapamycin: a novel anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

The rapamycin derivative RAD inhibits mesangial cell migration through the CDK-inhibitor p27KIP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Epstein-Barr virus and oncogenesis: from latent genes to tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Phosphatidylinositol 3-kinases in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

TSC2 regulates VEGF through mTOR-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

The role of PML in tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Malignant hematopoietic cells induce an increased expression of VEGFR-1 and VEGFR-3 on bone marrow endothelial cells via AKT and mTOR signalling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

The Hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1432-2277.2007.00610.X

10.1111/J.1432-2277.2007.00610.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference